Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors

Patent metadata

Field	Value
Publication number	US-11292802-B2
Application number	US-201816761286-A
Country	US
Kind code	B2
Filing date	Nov 5, 2018
Priority date	Nov 7, 2017
Publication date	Apr 5, 2022
Grant date	Apr 5, 2022

Abstract

The disclosure relates to compounds of formula I: Formula I which inhibit αV-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.

First claim

What is claimed is:

1. A compound of Formula I:

or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein:
X is a bond, -(alkylene)-, -(alkylene)-NR 7 —, -(alkylene)-O—, -(alkylene)-S—, —NR 7 —, —O—, or —S—;
R 1 is hydrogen, halo, or alkyl;
R 2 is —NHC(NH)NH 2 , —NH(dihydroimidazolyl), —NH(imidazolyl), —NH(tetrahydropyrimidinyl), —NH(pyridinyl), —NH(benzoimidazolyl), tetrahydronaphthyridinyl, naphthyridinyl, dihydropyridooxazinyl, tetrahydropyridopyrazinyl, tetrahydropyridoazepinyl, tetrahydropyridooxazepinyl, dihydroimidazoimidazolyl, or tetrahydroimidazopyrimidinyl, each optionally substituted with 1 or 2 independently selected alkyl substituents; or
X and R 2 , taken together, form —CH[CH 2 (tetrahydronaphthyridinyl)] 2 ;
R 3 is hydrogen, halo, or alkyl;
R 4 is hydrogen or Ar 1 ;
R 5 is hydrogen, —NHC(O)OCH 2 (phenyl), or —NHS(O) 2 Ar 1 ;
R 6 is hydrogen or alkyl;
R 7 is hydrogen or alkyl; and
each Ar 1 is independently dihydrobenzofuranyl, phenyl, naphthyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl, or quinoxalinyl, each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, cyano, alkyl, haloalkyl, OH, —O(alkyl), —O(haloalkyl), and —O-(alkylene)-cycloalkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
X is a bond or -(alkylene)-;
R 1 is hydrogen or halo;
R 2 is —NHC(NH)NH 2 , —NH(dihydroimidazolyl), —NH(imidazolyl), —NH(tetrahydropyrimidinyl), —NH(pyridinyl), —NH(benzoimidazolyl), tetrahydronaphthyridinyl, naphthyridinyl, dihydropyridooxazinyl, tetrahydropyridopyrazinyl, tetrahydropyridoazepinyl, tetrahydropyridooxazepinyl, dihydroimidazoimidazolyl, or tetrahydroimidazopyrimidinyl, each optionally substituted with 1 or 2 independently selected alkyl substituents;
R 3 is hydrogen;
R 4 is hydrogen or Ar 1 ;
R 5 is hydrogen, —NHC(O)OCH 2 (phenyl), or —NHS(O) 2 Ar 1 ;
R 6 is hydrogen or alkyl; and
each Ar 1 is independently dihydrobenzofuranyl, phenyl, naphthyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl, or quinoxalinyl, each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halo, cyano, alkyl, haloalkyl, OH, —O(alkyl), —O(haloalkyl), and —O-(alkylene)-cycloalkyl.

3. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X is a bond or -(alkylene)-.

4. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is hydrogen or halo.

5. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 is —NH(pyridinyl), tetrahydronaphthyridinyl, or naphthyridinyl, each optionally substituted with 1 or 2 independently selected alkyl substituents.

6. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is hydrogen.

7. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
R 4 is Ar 1 ; and
R 5 is hydrogen.

8. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
R 4 is hydrogen; and
R 5 is —NHC(O)OCH 2 (phenyl) or —NHS(O) 2 Ar 1 .

9. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each Ar 1 is independently phenyl, pyridinyl, or pyrimidinyl, each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, cyano, alkyl, haloalkyl, OH, —O(alkyl), —O(haloalkyl), and —O-(alkylene)-cycloalkyl.

10. The compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound, or pharmaceutically acceptable salt or stereoisomer thereof, is selected from the group consisting of:

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.

12. A method for inhibiting alpha-V integrin activity in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.

13. The method of claim 12 , wherein the patient has a disease, disorder, or condition selected from the group consisting of a cancer, an inflammatory disorder, osteoporosis, a pathological fibrosis, and transplant rejection.

14. The method of claim 13 , wherein the cancer is selected from the group consisting of bladder cancer, blood cancer, bone cancer, brain cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gallbladder cancer, genital cancer, genitourinary tract cancer, head cancer, kidney cancer, large intestine cancer, larynx cancer, liver cancer, lung cancer, muscle tissue cancer, neck cancer, oral cancer, nasal mucosa cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, spleen cancer, small intestine cancer, stomach cancer, testicular cancer, and thyroid cancer.

15. The method of claim 13 , wherein the pathological fibrosis is selected from the group consisting of cardiac fibrosis, dermal fibrosis, hepatic fibrosis, ocular fibrosis, pancreatic fibrosis, pulmonary fibrosis, and renal fibrosis.

16. The method of claim 12 , wherein the patient has a disease, disorder, or condition selected from the group consisting of chronic kidney disease, diabetic kidney disease, idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis, and systemic sclerosis.

Assignees

• Bristol Myers Squibb Co

Inventors

• Zhao Guohua
• Mignone James

Classifications

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• A61P19/10

  for osteoporosis · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/4985

  Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title